The story appears on

Page A12

August 25, 2016

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Business » Consumer

Sale marks warming of relations

ASTRAZENECA plans to sell its molecule antibiotics business to Pfizer in a deal that will be valued over US$1.5 billion when rights, royalties and other payments are included.

The sale marks a thawing of relations between the UK company and New York-based Pfizer after an acrimonious battle to avoid a takeover just a few years ago.

Under the deal, AstraZeneca will sell the commercialization and development rights in most markets globally outside the United States. It includes an upfront payment of US$550 million.

Luke Miels, the head of the antibiotics business unit at AstraZeneca, says the company is “pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases.”




 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend